Specify a stock or a cryptocurrency in the search bar to get a summary
Madrigal Pharmaceuticals Inc
YDO1Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428
Analytics
WallStreet Target Price
368.87 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures YDO1
Dividend Analytics YDO1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History YDO1
Stock Valuation YDO1
Financials YDO1
Results | 2019 | Dynamics |